(35) evaluated the Zirconium-89–Deferoxamine–durvalumab (89Zr-DFO-durvalumab), which consists of durvalumab, a human anti-PD-L1 mAb, that binds explicitly to PD-L1 expressed on tumor and immune cells. Here, CD274 is linked to neoplasm.